Zacks Research Upgrades Daiichi Sankyo (OTCMKTS:DSNKY) to Hold

Daiichi Sankyo (OTCMKTS:DSNKY) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.

Separately, Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Daiichi Sankyo Price Performance

DSNKY stock opened at $19.00 on Monday. The firm has a market cap of $35.39 billion, a P/E ratio of 22.09, a price-to-earnings-growth ratio of 2.61 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $27.50. The stock has a 50-day simple moving average of $17.67 and a 200-day simple moving average of $17.27.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts predict that Daiichi Sankyo will post 0.97 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.